Effect of nerandomilast on survival in patients with pulmonary fibrosis
European Respiratory Journal · 30.07.2026 · 2600338
DOI: 10.1183/13993003.00338-2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 30.07.2026. Verfasst von Justin M Oldham und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA oldhamj@med.umich.edu. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The FIBRONEER-IPF and FIBRONEER-ILD trials were supported by Boehringer Ingelheim International GmbH..
Abstract (Originalsprache)
Background
In the placebo-controlled FIBRONEER-IPF and FIBRONEER-ILD trials in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), the key secondary endpoint was not met but numerical benefits of nerandomilast on time to death (a secondary endpoint) were observed. We further investigated the robustness of the effect of nerandomilast on survival.
Methods
In both trials, the primary analysis of time to death was based on all deaths except those after lung transplant, using a Cox proportional hazards model. We performed sensitivity analyses of the impact of covariates, tipping point analyses, and supplementary analyses of deaths during and shortly after treatment and the impact of intercurrent events. We assessed time to death by exposure to nerandomilast (trough concentration at steady state).
Results
Based on pooled data from both trials, over the whole follow-up period (mean:16.7 months), the risk of death versus placebo was reduced by 33% (hazard ratio: 0.67 [95% CI: 0.49, 0.90]; p=0.009) with nerandomilast 9 mg bid and by 43% (hazard ratio: 0.57 [95% CI: 0.41, 0.78]; p
Autor:innen und Institutionen
- Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA oldhamj@med.umich.edu.
- Division of Rheumatology, McGovern Medical School, UTHealth Houston, Houston, Texas, USA.
- Clinical Research Center, Mihara General Hospital, Saitama, Japan.
- Nippon Medical School, Tokyo, Japan.
- National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
- Department of Rheumatology, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Shervin Assassi, Vincent Cottin, Toby M Maher, Claudia Valenzuela
Förderung
- The FIBRONEER-IPF and FIBRONEER-ILD trials were supported by Boehringer Ingelheim International GmbH.
Zitieren
APA
Oldham, J. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A. M., Kreuter, M., Maher, T. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., Choy, S., Gu, H., Weimann, G., Ritter, I., Stowasser, S., Zoz, D. F., & Martinez, F. J. (2026). Effect of nerandomilast on survival in patients with pulmonary fibrosis. European Respiratory Journal, 2600338. https://doi.org/10.1183/13993003.00338-2026
Vancouver
Oldham JM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, et al. Effect of nerandomilast on survival in patients with pulmonary fibrosis. European Respiratory Journal. 2026:2600338. doi:10.1183/13993003.00338-2026
BibTeX
@article{Oldham2026,
author = {Oldham, Justin M and Assassi, Shervin and Azuma, Arata and Cottin, Vincent and Hoffmann-Vold, Anna-Maria and Kreuter, Michael and Maher, Toby M and Richeldi, Luca and Valenzuela, Claudia and Wijsenbeek, Marlies S and Choy, Steve and Gu, Hui and Weimann, Gerrit and Ritter, Ivana and Stowasser, Susanne and Zoz, Donald F and Martinez, Fernando J},
title = {Effect of nerandomilast on survival in patients with pulmonary fibrosis},
journal = {European Respiratory Journal},
year = {2026},
pages = {2600338},
doi = {10.1183/13993003.00338-2026}
}
EUVIMED